|
|
Post by centralcoastinvestor on Jun 18, 2018 9:53:19 GMT -5
I just saw this posted on Stocktwits. This may be the first of many publications to come. Good to see. Recommendations for Initiating Use of Afrezza Inhaled Insulin in Individuals with Type 1 Diabetes www.liebertpub.com/doi/full/10.1089/dia.2017.0463 |
|
|
|
Post by mannmade on Jun 18, 2018 10:06:01 GMT -5
Yes I read the article. Very positive for AFREZZA and very pragmatic in its approach in my opinion. Hard to understand why not doing better when you read an article like this...
|
|
|
|
Post by sellhighdrinklow on Jun 18, 2018 10:11:19 GMT -5
Spot on article!
|
|
|
|
Post by xanet on Jun 18, 2018 13:42:09 GMT -5
Finally! This would be a great reference to use in correcting and expanding the anemic Wikipedia article on inhaled insulin, if anyone has the time and interest. Problem in the past was lack of good, peer reviewed content, so this is a welcome article indeed.
|
|
|
|
Post by oldfishtowner on Jun 18, 2018 14:18:10 GMT -5
Should be in the bag of every sales rep as a handout to physicians.
|
|
|
|
Post by kc on Jun 19, 2018 21:00:04 GMT -5
I have said 100 times over 4 years —- Doctors are very slow to change what they think is working as they are just old school steady Eddie’s. They have been wined and dined by the big 3 for too many years and enjoy the perks.
If we stay financially viable we will make it and be a blockbuster game changing product for diabetics.
|
|
|
|
Post by kc on Jun 19, 2018 21:08:53 GMT -5
Does anybody know what this Abstract says about Afrezza? www.ncbi.nlm.nih.gov/pubmed/29718785/Postgrad Med. 2018 May;130(4):409-410. doi: 10.1080/00325481.2018.1472509. Epub 2018 May 14.Finally, after 56 years of type 1 diabetes: a regimen that works. Bell DSH1. Author information Abstract Prior to the availability of degludec and regular human insulin inhalation powder in the type 1 diabetic patient glycemic control with subcutaneous insulin injections was difficult to obtain due to nocturnal, pre-prandial and often severe hypoglycemia as well as post-prandial hyperglycemia and hypoglycemia due to 'stacking' of insulin. A 62-year-old female with type 1 diabetes for 56 years who could not be controlled with continuous subcutaneous insulin aspart infusion obtained glycemic control without significant hypoglycemia or increased post-prandial glycemic excursions utilizing degludec insulin for basal needs and technosphere before meals and between meals if needed. The availability of degludec and technosphere insulin improved the management of brittle type 1 diabetes.KEYWORDS: Diabetes mellitus type 1; degludec insulin; hypoglycemia; post-prandial hyperglycemia; regular human insulin inhalation powder |
|
|
|
Post by kc on Jun 19, 2018 21:48:15 GMT -5
Insulin degludec is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba.
Afrezza and Tresiba.
|
|
|
|
Post by slugworth008 on Jun 19, 2018 22:03:26 GMT -5
Should be in the bag of every sales rep as a handout to physicians. Do the sales reps actually see physicians anymore? Given the script numbers me thinks not. IMO |
|
|
|
Post by centralcoastinvestor on Jun 19, 2018 23:12:44 GMT -5
Should be in the bag of every sales rep as a handout to physicians. Do the sales reps actually see physicians anymore? Given the script numbers me thinks not. IMO As a matter of fact, they do. Two weeks ago, I went to my Primary Care Physician whom I’ve seen for nearly 30 years. I have talked to him about Afrezza every 6 months for the last 3 years. He is used to me pestering him about Afrezza. His office does prescribe Afrezza now. He told me at my last appointment that his office had a MannKind rep visit and make a presentation to his offices. He said they did a good job of telling the Afrezza story. I’m on the Central Coast of California which is more rural so I thought it was great that a rep made it here. |
|
|
|
Post by agedhippie on Jun 20, 2018 6:07:00 GMT -5
The authors' disclosure at the bottom of the article as well as the acknowledgement is not going to help the idea of impartiality. In fairness I think the Mannkind assistance looks like it was in funding Parking to clean up the article which is not uncommon. It helps that the editor-in-chief is on the Mannkind SAB.
The good side is that it gets the dosing information out there in a way that is not going to get Mannkind into trouble with the FDA.
|
|
